Log in

NYSEAMERICAN:CVRS - Corindus Vascular Robotics Stock Price, Forecast & News

$4.27
0.00 (0.00 %)
(As of 11/27/2019)
Today's Range
$4.27
Now: $4.27
$4.27
50-Day Range N/A
52-Week Range
$0.78
Now: $4.27
$4.40
VolumeN/A
Average Volume1.99 million shs
Market Capitalization$891.08 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Corindus Vascular Robotics, Inc designs, manufactures, and sells robotic-assisted systems for use in interventional vascular procedures in the United States and internationally. The company offers CorPath system, a medical device with robotic-assisted precision for coronary and peripheral interventional procedures. Its CorPath system allows the physician to perform procedures with a control console located within an interventional cockpit; and CorPath GRX system enables the precise robotic-assisted control of guide catheters, guidewires, and balloon/stent devices from the safety of a radiation-shielded interventional cockpit. Read More…

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Medical Appliances & Equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:CVRS
Previous SymbolNYSEMKT:CVRS
CUSIPN/A
CIKN/A
Phone+1-508-6533335

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees90
Market Cap$891.08 million
Next Earnings DateN/A
OptionableNot Optionable

Receive CVRS News and Ratings via Email

Sign-up to receive the latest news and ratings for CVRS and its competitors with MarketBeat's FREE daily newsletter.


Corindus Vascular Robotics (NYSEAMERICAN:CVRS) Frequently Asked Questions

What is Corindus Vascular Robotics' stock symbol?

Corindus Vascular Robotics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CVRS."

How were Corindus Vascular Robotics' earnings last quarter?

Corindus Vascular Robotics Inc (NYSEAMERICAN:CVRS) announced its quarterly earnings results on Tuesday, August, 7th. The medical equipment provider reported ($0.06) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.05) by $0.01. The medical equipment provider had revenue of $1.67 million for the quarter, compared to the consensus estimate of $3 million. View Corindus Vascular Robotics' Earnings History.

What price target have analysts set for CVRS?

1 brokers have issued 1-year price objectives for Corindus Vascular Robotics' stock. Their forecasts range from $4.28 to $4.28. On average, they anticipate Corindus Vascular Robotics' stock price to reach $4.28 in the next twelve months. This suggests a possible upside of 0.2% from the stock's current price. View Analyst Price Targets for Corindus Vascular Robotics.

What is the consensus analysts' recommendation for Corindus Vascular Robotics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corindus Vascular Robotics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Corindus Vascular Robotics.

Has Corindus Vascular Robotics been receiving favorable news coverage?

News headlines about CVRS stock have been trending somewhat negative on Saturday, according to InfoTrie. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Corindus Vascular Robotics earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave media stories about the medical equipment provider a news buzz of 7.0 out of 10, indicating that recent news coverage is likely to have an effect on the stock's share price in the near future. View News Stories for Corindus Vascular Robotics.

Are investors shorting Corindus Vascular Robotics?

Corindus Vascular Robotics saw a decline in short interest during the month of October. As of October 15th, there was short interest totalling 8,700,000 shares, a decline of 7.6% from the September 15th total of 9,420,000 shares. Based on an average daily trading volume, of 3,240,000 shares, the days-to-cover ratio is presently 2.7 days. Approximately 6.8% of the company's shares are sold short. View Corindus Vascular Robotics' Current Options Chain.

Who are some of Corindus Vascular Robotics' key competitors?

What other stocks do shareholders of Corindus Vascular Robotics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corindus Vascular Robotics investors own include Amarin (AMRN), TransEnterix (TRXC), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), Helios and Matheson Analytics (HMNY), TherapeuticsMD (TXMD), Viking Therapeutics (VKTX), Exelixis (EXEL) and NVIDIA (NVDA).

Who are Corindus Vascular Robotics' key executives?

Corindus Vascular Robotics' management team includes the folowing people:
  • Mr. Mark J. Toland, CEO, Pres & Director (Age 49)
  • Mr. David W. Long, CFO, Sr. VP, Sec. & Treasurer (Age 49)
  • Mr. Douglas Teany, Chief Operating Officer (Age 47)
  • Ms. Nora Dutta, Sr. VP of HR
  • Dr. J. Aaron Grantham, Chief Medical Officer of Cardiovascular

Who are Corindus Vascular Robotics' major shareholders?

Corindus Vascular Robotics' stock is owned by a number of of institutional and retail investors. Top institutional investors include State Street Corp (0.91%), ARP Americas LP (0.64%), GABELLI & Co INVESTMENT ADVISERS INC. (0.45%), Gabelli Funds LLC (0.37%), Millennium Management LLC (0.28%) and K2 Principal Fund L.P. (0.27%). Company insiders that own Corindus Vascular Robotics stock include Hudson Executive Capital Lp and Louis A Cannon. View Institutional Ownership Trends for Corindus Vascular Robotics.

Which major investors are selling Corindus Vascular Robotics stock?

CVRS stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Masters Capital Management LLC and Stifel Financial Corp. View Insider Buying and Selling for Corindus Vascular Robotics.

Which major investors are buying Corindus Vascular Robotics stock?

CVRS stock was purchased by a variety of institutional investors in the last quarter, including ARP Americas LP, GABELLI & Co INVESTMENT ADVISERS INC., Gabelli Funds LLC, K2 Principal Fund L.P., Barclays PLC, Havens Advisors LLC, State Street Corp and Harvest Management LLC. Company insiders that have bought Corindus Vascular Robotics stock in the last two years include Hudson Executive Capital Lp and Louis A Cannon. View Insider Buying and Selling for Corindus Vascular Robotics.

How do I buy shares of Corindus Vascular Robotics?

Shares of CVRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Corindus Vascular Robotics' stock price today?

One share of CVRS stock can currently be purchased for approximately $4.27.

How big of a company is Corindus Vascular Robotics?

Corindus Vascular Robotics has a market capitalization of $891.08 million. Corindus Vascular Robotics employs 90 workers across the globe.View Additional Information About Corindus Vascular Robotics.

What is Corindus Vascular Robotics' official website?

The official website for Corindus Vascular Robotics is http://www.corindus.com/.

How can I contact Corindus Vascular Robotics?

Corindus Vascular Robotics' mailing address is 309 Waverley Oaks Rd Ste 105, WALTHAM, MA 02452-8451, United States. The medical equipment provider can be reached via phone at +1-508-6533335.


MarketBeat Community Rating for Corindus Vascular Robotics (NYSEAMERICAN CVRS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  368 (Vote Outperform)
Underperform Votes:  432 (Vote Underperform)
Total Votes:  800
MarketBeat's community ratings are surveys of what our community members think about Corindus Vascular Robotics and other stocks. Vote "Outperform" if you believe CVRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CVRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/14/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel